From: CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
Correlation of CA916798 | Pearson R | P Value |
---|---|---|
vs. CCNB1 | 0.703 | < 0.0001 |
vs. CCNB2 | 0.6812 | < 0.0001 |
vs. CCNA2 | 0.6256 | < 0.0001 |
vs. CCNE1 | 0.5929 | < 0.0001 |
vs. CCNE2 | 0.5215 | < 0.0001 |
vs. CCNO | 0.286 | < 0.0001 |
vs. CCNI2 | 0.1826 | < 0.0001 |
vs. CCNC | 0.1711 | < 0.0001 |
vs. CCNT2 | -0.00597 | 0.8863 |
vs. CCNH | -0.01291 | 0.7572 |
vs. CCNG2 | -0.01784 | 0.6692 |
vs. CCNA1 | -0.1075 | 0.0098 |
vs. CCNT1 | -0.1118 | 0.0072 |
vs. CCNG1 | -0.1145 | 0.006 |
vs. CCND1 | -0.1427 | 0.0006 |
vs. CCNI | -0.1722 | < 0.0001 |
vs. CCNB3 | -0.1939 | < 0.0001 |
vs. CCND3 | -0.2588 | < 0.0001 |
vs. CCND2 | -0.3642 | < 0.0001 |